Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013, Article ID 196541, 9 pages
http://dx.doi.org/10.1155/2013/196541
Research Article

Profiling the Prognosis of Gastric Cancer Patients: Is It Worth Correlating the Survival with the Clinical/Pathological and Molecular Features of Gastric Cancers?

1Surgical and Medical Department of Translational Medicine, Sant’Andrea Hospital, Faculty of Medicine and Psychology, University of Rome “La Sapienza”, Via di Grottarossa 1035-39, 00189 Rome, Italy
2Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, Faculty of Medicine and Psychology, University of Rome “La Sapienza”, Via di Grottarossa 1035-39, 00189 Rome, Italy

Received 27 August 2013; Accepted 27 September 2013

Academic Editors: R. Lorenzetti, T. Shimatani, T. K. Ti, and T. Uraoka

Copyright © 2013 Laura Lorenzon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Kamangar, G. M. Dores, and W. F. Anderson, “Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world,” Journal of Clinical Oncology, vol. 24, no. 14, pp. 2137–2150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. AIRTUM, “I tumori in Italia: Rapporto,” 2006, http://www.registri-tumori.it/incidenza1998-2002/gruppi.html.
  3. American Joint Committee on Cancer, Manual for Staging of Cancer, Lippincott-Raven, New York, NY, USA, 4th edition, 1992.
  4. American Joint Committee on Cancer, Manual for Staging of Cancer, Lippincott-Raven, New York, NY, USA, 5th edition, 1997.
  5. M. S. Karpeh, L. Leon, D. Klimstra, and M. F. Brennan, “Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients,” Annals of Surgery, vol. 232, no. 3, pp. 362–371, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. American Joint Committee on Cancer, Manual for Staging of Cancer, Springer, 7th edition, 2009.
  7. Y. Kodera, Y. Yamamura, Y. Shimizu et al., “Metastatic gastric lymph node rate is a significant prognostic factor for resectable stage IV stomach cancer,” Journal of the American College of Surgeons, vol. 185, no. 1, pp. 65–69, 1997. View at Google Scholar · View at Scopus
  8. D.-Z. Xu, Q.-R. Geng, Z.-J. Long et al., “Positive lymph node ratio is an independent prognostic factor in gastric cancer after D2 resection regardless of the examined number of lymph nodes,” Annals of Surgical Oncology, vol. 16, no. 2, pp. 319–326, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Marchet, S. Mocellin, A. Ambrosi et al., “The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients,” Annals of Surgery, vol. 245, no. 4, pp. 543–552, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Alatengbaolide, D. Lin, Y. Li et al., “Lymph node ratio is an independent prognostic factor in gastric cancer after curative Resection (R0) regardless of the examined number of lymph nodes,” American Journal of Clinical Oncology, vol. 36, no. 4, pp. 325–330, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. D. I. Park, J. W. Yun, J. H. Park et al., “HER-2/neu amplification is an independent prognostic factor in gastric cancer,” Digestive Diseases and Sciences, vol. 51, no. 8, pp. 1371–1379, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Tanner, M. Hollmén, T. T. Junttila et al., “Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab,” Annals of Oncology, vol. 16, no. 2, pp. 273–278, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. Y.-J. Bang, E. Van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S. R. Lee, H. O. Kim, B. H. Son, J. H. Shin, and C. H. Yoo, “Prognostic significance of the metastatic lymph node ratio in patients with gastric cancer,” World Journal of Surgery, vol. 36, no. 5, pp. 1096–1101.
  15. F. Kamangar, G. M. Dores, and W. F. Anderson, “Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world,” Journal of Clinical Oncology, vol. 24, no. 14, pp. 2137–2150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Cunningham, W. H. Allum, S. P. Stenning et al., “Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer,” New England Journal of Medicine, vol. 355, no. 1, pp. 11–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. J. Horner, L. A. G. Ries, M. Krapcho et al., “SEER Cancer Statistics Review, 1975–2006,” 2009, http://seer.cancer.gov/csr/1975_2006/.
  18. S. C. Cunningham, F. Kamangar, M. P. Kim et al., “Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution,” Journal of Gastrointestinal Surgery, vol. 9, no. 5, pp. 718–725, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. C. A. Hudis, “Trastuzumab—mechanism of action and use in clinical practice,” New England Journal of Medicine, vol. 357, no. 1, pp. 39–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones et al., “Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer,” New England Journal of Medicine, vol. 353, no. 16, pp. 1659–1672, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Smith, M. Procter, R. D. Gelber et al., “2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial,” The Lancet, vol. 369, no. 9555, pp. 29–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Espín, A. Bianchi, S. Llorca et al., “Metastatic lymph node ratio versus number of metastatic lymph nodes as a prognostic factor in gastric cancer,” European Journal of Surgical Oncology, vol. 38, no. 6, pp. 497–502, 2012. View at Publisher · View at Google Scholar · View at Scopus